New-onset erythrodermic psoriasis associated with antiepileptic drug use

Authors

  • James Feng Geisel School of Medicine at Dartmouth, Hanover, NH, USA Author
  • Payal Shah Department of Dermatology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA Author
  • Jeffrey Cloutier Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, NH, USA Author
  • Jonathan Glass Department of Dermatology, Dartmouth Health, Lebanon, NH, USA Author
  • Dorothea Barton Department of Dermatology, Dartmouth Health, Lebanon, NH, USA Author

DOI:

https://doi.org/10.25251/5bv66v50

Keywords:

antiepileptics, drug reaction, erythroderma, psoriasis

Abstract

Erythrodermic psoriasis is a severe and potentially life-threatening dermatologic condition that can be triggered or unmasked by medications. We report the case of a 73-year-old patient who developed new-onset erythrodermic psoriasis following treatment with antiepileptic drugs (AEDs), specifically carbamazepine and levetiracetam, for autoimmune encephalitis. Despite discontinuation of the AEDs, the patient’s condition persisted and improved only after systemic biological therapy. Clinical presentation, together with histopathologic findings, supported a diagnosis of new-onset psoriasis rather than a drug-induced psoriasiform reaction. This case highlights the importance of recognizing AEDs as potential triggers for psoriasis in patients with no prior history. Given the severe complications associated with erythroderma, timely diagnosis and initiation of appropriate therapy are essential. Clinicians should maintain a high index of suspicion for medication-induced dermatologic conditions in patients presenting with new or progressive skin eruptions.

References

1. Mani R, Monteleone C, Schalock PC, et al. Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature. Seizure. 2019;71:270-278. [PMID: 31491658].

2. Brenner S, Wolf R, Landau M, Politi Y. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci. 1994;30:283-286. [PMID: 8175330].

3. Gencler OS, Gencler B, Altunel CT, Arslan N. Levetiracetam induced psoriasiform drug eruption: a rare case report. Saudi Pharm J. 2015;23:720-722. [PMID: 26702269].

4. Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care. 2015;28:228-238. [PMID: 25882661].

5. Egeberg A, Thyssen JP, Gislason GH, Skov L. Prognosis after Hospitalization for Erythroderma. Acta Derm Venereol. 2016;96:959-962. [PMID: 27140225].

6. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017;7:87-94. [PMID: 29387611].

7. Lu J, Lu Y. Paradoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?. J Transl Autoimmun. 2023;7:100211. [PMID: 37731549].

8. Balakirski G, Burmann SN, Hofmann SC, Kreuter A. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis. J Dermatolog Treat. 2023;34:2258240. [PMID: 37705378].

9. Tsiogka A, Liakou AI, Agiasofitou E, et al. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa. Dermatology. 2023;239:937-941. [PMID: 37579735].

10. Cutroneo P, Ingrasciotta Y, Isgrò V, et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther. 2021;34:e14830. [PMID: 33527643].

Downloads

Published

01/05/2026